Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Early Phase 1
5(62.5%)
Phase 2
2(25.0%)
Phase 1
1(12.5%)
8Total
Early Phase 1(5)
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07444437Phase 2Not Yet Recruiting

LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

Role: lead

NCT07310784Phase 2Recruiting

A Phase II Trial of LM103 in Advanced Melanoma

Role: lead

NCT06697665Early Phase 1Recruiting

An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours

Role: lead

NCT06695689Early Phase 1Recruiting

An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours

Role: lead

NCT05971589Early Phase 1Not Yet Recruiting

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Role: lead

NCT05971576Early Phase 1Not Yet Recruiting

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Role: lead

NCT05941936Early Phase 1Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Role: lead

NCT05366478Phase 1Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Role: lead

All 8 trials loaded